Edition:
United States

Rocket Pharmaceuticals Inc (RCKT.OQ)

RCKT.OQ on NASDAQ Stock Exchange Global Market

22.79USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$22.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
102,348
52-wk High
$25.84
52-wk Low
$5.06

Latest Key Developments (Source: Significant Developments)

Rocket Pharmaceuticals Reports Q1 Loss Per Share Of $0.42
Friday, 11 May 2018 07:00am EDT 

May 11 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q1 LOSS PER SHARE $0.42.  Full Article

Rocket Pharmaceuticals Reports Full-Year 2017 Results
Tuesday, 6 Mar 2018 07:00am EST 

March 6 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.ROCKET PHARMACEUTICALS INC - CASH AS OF DECEMBER 31, 2017 FOR ROCKET PHARMACEUTICALS LTD. WAS $18.1 MILLION.  Full Article

Inotek files for preliminary proxy statement for proposed merger with Rocket Pharmaceuticals
Thursday, 12 Oct 2017 05:20pm EDT 

Oct 12 (Reuters) - Inotek Pharmaceuticals Corp :Inotek Pharmaceuticals announces filing of preliminary proxy statement for proposed merger with clinical-stage gene therapy company, Rocket Pharmaceuticals.Inotek Pharmaceuticals Corp - ‍additional first-in-human results from up to three programs expected in 2018​.Inotek Pharmaceuticals Corp - ‍merger is expected to close in Q1 of 2018​.  Full Article

‍Adage Capital Partners reports 5.55 pct stake in Inotek Pharmaceuticals
Thursday, 5 Oct 2017 10:52am EDT 

Oct 5 (Reuters) - Inotek's :‍Adage Capital Partners reports 5.55 percent stake in Inotek Pharmaceuticals as of September 26 - SEC filing​.‍Adage Capital Partners says acquired shares of Inotek Pharma because they represent an "attractive investment opportunity"​.‍Adage Capital Partners - Acquired shares of Inotek's common stock pursuant to investment strategies, including merger arbitrage and event driven strategies​.  Full Article

Braden Leonard reports 5.6 pct passive stake in Inotek Pharmaceuticals as of Sept 13 - SEC Filing
Wednesday, 20 Sep 2017 04:16pm EDT 

Sept 20 (Reuters) - Inotek Pharmaceuticals Corp :Braden M Leonard reports 5.6 percent passive stake in Inotek Pharmaceuticals Corp as of Sept 13, 2017 - SEC Filing.  Full Article

Inotek Pharmaceuticals announces merger agreement with Rocket Pharmaceuticals to advance pipeline of first-in-class gene therapies for rare diseases
Tuesday, 12 Sep 2017 04:15pm EDT 

Sept 12 (Reuters) - Inotek Pharmaceuticals Corp :Inotek Pharmaceuticals announces merger agreement with Rocket Pharmaceuticals to advance pipeline of first-in-class gene therapies for rare diseases.Inotek Pharmaceuticals Corp - ‍Rocket shareholders are expected to own approximately 81% of combined company​.Inotek Pharmaceuticals Corp - ‍Shareholders of Rocket will receive shares of newly issued inotek common shares in a private placement​.Says transaction has been unanimously approved by board of directors of both companies.Inotek Pharmaceuticals Corp - ‍Current Inotek shareholders will own approximately 19% of combined company​.Inotek Pharmaceuticals Corp - ‍It is reducing its workforce by approximately 60% to a total of 7 full-time employees​.Inotek Pharmaceuticals Corp - ‍All affected employees are being offered severance and transition benefits​.Inotek Pharmaceuticals Corp - ‍Gaurav Shah will serve as chief executive officer of combined company​.Inotek Pharmaceuticals Corp - ‍Combined company board of directors will be chaired by Roderick Wong, managing partner of RTW Investments​.  Full Article

Inotek Pharmaceuticals qtrly loss per share $0.24
Thursday, 3 Aug 2017 04:01pm EDT 

Aug 3 (Reuters) - Inotek Pharmaceuticals Corp :Inotek Pharmaceuticals Corporation reports second quarter 2017 financial results and operational highlights.Qtrly loss per share $0.24.  Full Article

Inotek Pharmaceuticals says evaluating strategic alternatives
Friday, 7 Jul 2017 04:01pm EDT 

July 7 (Reuters) - Inotek Pharmaceuticals Corp ::Inotek Pharmaceuticals announces top-line results of phase 2 fixed-dose combination trial of trabodenoson and provides corporate update.Inotek Pharmaceuticals Corp - company evaluating strategic alternatives.Inotek Pharmaceuticals Corp - trabodenoson FDC demonstrated moderate IOP reduction over latanoprost alone when dosed in morning.Inotek Pharmaceuticals Corp - ‍has engaged Perella Weinberg Partners as a financial advisor to assist with strategic review process​.Inotek Pharmaceuticals Corp - trabodenoson FDC had comparable efficacy dosed in afternoon, and at day 56 over latanoprost alone.Inotek Pharmaceuticals - addition of trabodenoson to latanoprost offered no clinically meaningful advantage in eye pressure reduction over latanoprost alone.Inotek - based on these results and results for phase 3 matrx-1 monotherapy trial, co evaluating future clinical potential of trabodenoson.  Full Article

Inotek Pharmaceuticals Corp posts Q1 loss per share $0.40
Wednesday, 10 May 2017 07:00am EDT 

May 10 (Reuters) - Inotek Pharmaceuticals Corp :Inotek Pharmaceuticals Corporation reports first quarter 2017 financial results and operational highlights.Inotek Pharmaceuticals Corp qtrly loss per share $0.40.Inotek Pharmaceuticals Corp qtrly research and development expenses were $7.1 million, compared to $7.6 million for quarter ended March 31, 2016.Inotek Pharmaceuticals - communicated with U.S. FDA regarding matrx-1 results, FDA in agreement that trial did not meet its primary efficacy endpoint.Inotek Pharmaceuticals - is evaluating potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases.  Full Article

Inotek completes patient recruitment in phase 2 trial of a fixed-dose combination of Trabodenoson and Latanoprost
Tuesday, 11 Apr 2017 07:00am EDT 

Inotek Pharmaceuticals Corp : Inotek completes patient recruitment in phase 2 trial of a fixed-dose combination (fdc) of Trabodenoson and Latanoprost .Inotek Pharmaceuticals Corp - Top-line data from FDC study are expected in July.  Full Article

BRIEF-Rocket Pharmaceuticals Presents Updated Data From Phase 1/2 Gene Therapy Trial Of Rp-L102

* ROCKET PHARMACEUTICALS PRESENTS UPDATED DATA FROM PHASE 1/2 GENE THERAPY TRIAL OF RP-L102 IN PATIENTS WITH FANCONI ANEMIA AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) ANNUAL MEETING